Literature DB >> 24380501

Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening.

Vicki B Benard1, Mona Saraiya, April Greek, Nikki A Hawkins, Katherine B Roland, Diane Manninen, Donatus U Ekwueme, Jacqueline W Miller, Elizabeth R Unger.   

Abstract

BACKGROUND: The recommended screening interval when using the Papanicolaou (Pap) and human papillomavirus (HPV) test (co-testing) is 5 years. However because providers are reluctant to extend the screening interval, we launched a study to identify barriers to appropriate use of the co-test and to implement an educational intervention to promote evidence-based screening practices. This article provides an overview of the study including the multi-component intervention and participant demographics.
METHODS: The study was conducted in 15 clinics associated with 6 Federally Qualified Health Centers (FQHCs) in Illinois. Each clinic received HPV tests to administer with routine Pap tests among enrolled patients (n=2,246) and was assigned to a study arm: intervention arm (n=7) received a multi-component educational intervention (small media, academic detailing, and website) for providers and printed educational materials for patients, and control arm (n=8) received printed copies of general guidelines. Clinic coordinators (n=15), providers (n=98), and patients (n=984) completed baseline surveys to assess screening practices.
RESULTS: Providers reported an average age of 41.3 years and were predominately female, non-Hispanic, and white. Patients reported an average age of 45.0 years and nearly two-thirds were Hispanic or black. Of the 2,246 patients, 89% had a normal co-test. Lessons learned from the study included the importance of buy-in at a high level in the organization, a champion provider, and a clinical coordinator devoted to the study.
CONCLUSION: Materials from this study can be adapted to educate providers and patients on appropriate use of the co-test and encourage extended screening intervals as a safe and effective practice.

Entities:  

Mesh:

Year:  2013        PMID: 24380501      PMCID: PMC4386595          DOI: 10.1089/jwh.2013.4655

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  19 in total

1.  A new readability yardstick.

Authors:  R FLESCH
Journal:  J Appl Psychol       Date:  1948-06

2.  Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers.

Authors:  Nikki A Hawkins; Vicki B Benard; April Greek; Katherine B Roland; Diane Manninen; Mona Saraiya
Journal:  Prev Med       Date:  2013-09-05       Impact factor: 4.018

3.  ACOG Practice Bulletin no. 109: Cervical cytology screening.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

4.  Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Authors:  Mona Saraiya; Zahava Berkowitz; K Robin Yabroff; Louise Wideroff; Sarah Kobrin; Vicki Benard
Journal:  Arch Intern Med       Date:  2010-06-14

5.  Benefits and costs of using HPV testing to screen for cervical cancer.

Authors:  Jeanne S Mandelblatt; William F Lawrence; Sharita Mizell Womack; Denise Jacobson; Bin Yi; Yi-ting Hwang; Karen Gold; James Barter; Keerti Shah
Journal:  JAMA       Date:  2002-05-08       Impact factor: 56.272

Review 6.  Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders.

Authors:  Roy C Baron; Stephanie Melillo; Barbara K Rimer; Ralph J Coates; Jon Kerner; Nancy Habarta; Sajal Chattopadhyay; Susan A Sabatino; Randy Elder; Kimberly Jackson Leeks
Journal:  Am J Prev Med       Date:  2010-01       Impact factor: 5.043

7.  Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007.

Authors:  K Robin Yabroff; Mona Saraiya; Helen I Meissner; David A Haggstrom; Louise Wideroff; Gigi Yuan; Zahava Berkowitz; William W Davis; Vicki B Benard; Steven S Coughlin
Journal:  Ann Intern Med       Date:  2009-11-03       Impact factor: 25.391

8.  Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Joshua A Salomon; Karen M Kuntz; Sue J Goldie
Journal:  J Natl Cancer Inst       Date:  2008-02-26       Impact factor: 13.506

9.  Cost-effectiveness of primary cytology and HPV DNA cervical screening.

Authors:  Peter Bistoletti; Karin Sennfält; Joakim Dillner
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

10.  Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting.

Authors:  Philip E Castle; Barbara Fetterman; Nancy Poitras; Thomas Lorey; Ruth Shaber; Walter Kinney
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.623

View more
  8 in total

1.  Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in U.S. Federally Qualified Health Centers.

Authors:  Katherine B Roland; Vicki B Benard; April Greek; Nikki A Hawkins; Mona Saraiya
Journal:  Vaccine       Date:  2014-08-12       Impact factor: 3.641

2.  Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.

Authors:  Mona Saraiya; Vicki B Benard; April A Greek; Martin Steinau; Sonya Patel; L Stewart Massad; George F Sawaya; Elizabeth R Unger
Journal:  Am J Obstet Gynecol       Date:  2014-05-06       Impact factor: 8.661

3.  Racial and ethnic differences in human papillomavirus positivity and risk factors among low-income women in Federally Qualified Health Centers in the United States.

Authors:  Lavinia Lin; Vicki B Benard; April Greek; Nikki A Hawkins; Katherine B Roland; Mona Saraiya
Journal:  Prev Med       Date:  2015-09-09       Impact factor: 4.018

4.  Changes in Knowledge and Beliefs About Human Papillomavirus and Cervical Cancer Screening Intervals in Low-Income Women After an Educational Intervention.

Authors:  Katherine B Roland; Vicki B Benard; April Greek; Nikki A Hawkins; Lavinia Lin
Journal:  J Prim Care Community Health       Date:  2016-01-13

Review 5.  Interventions targeted at women to encourage the uptake of cervical screening.

Authors:  Helen Staley; Aslam Shiraz; Norman Shreeve; Andrew Bryant; Pierre Pl Martin-Hirsch; Ketankumar Gajjar
Journal:  Cochrane Database Syst Rev       Date:  2021-09-06

6.  Provider beliefs associated with cervical cancer screening interval recommendations: A pilot study in Federally Qualified Health Centers.

Authors:  Katherine B Roland; April Greek; Nikki A Hawkins; Lavinia Lin; Vicki B Benard
Journal:  Prev Med Rep       Date:  2015

7.  Multimodal MRI Analysis of Cervical Cancer on the Basis of Artificial Intelligence Algorithm.

Authors:  Bin Wang; Yuanyuan Zhang; Chunyan Wu; Fen Wang
Journal:  Contrast Media Mol Imaging       Date:  2021-11-08       Impact factor: 3.161

8.  Communication practices about HPV testing among providers in Federally Qualified Health Centers.

Authors:  Lavinia Lin; Vicki B Benard; April Greek; Katherine B Roland; Nikki A Hawkins; Mona Saraiya
Journal:  Prev Med Rep       Date:  2015
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.